XENE EBITDA | XENON PHARMACEUTICALS INC.

XENON PHARMACEUTICALS INC. (XENE) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$123.16M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$112.33M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$96.34M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$94.23M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2012-12-31 to 2014-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$123.16M	(m)	(m)	(m)	$275.00K*	-$95.39M*	(m)	$99.22M	(m)	-$585.00K
2026-03-31	Reported	(m)	-$112.33M	(m)	(m)	(m)	$133.00K	-$88.90M	(m)	$88.51M	(m)	-$2.57M
2025-09-30	Reported	(m)	-$96.34M	(m)	(m)	(m)	$281.00K*	-$71.75M*	(m)	$77.05M	(m)	$677.00K
2025-06-30	Reported	(m)	-$94.23M	(m)	(m)	(m)	$157.00K*	-$64.23M*	(m)	$74.98M	(m)	-$626.00K
2025-03-31	Reported	(m)	-$72.74M	(m)	(m)	(m)	$43.00K	-$61.65M	(m)	$61.20M	(m)	$427.00K
2024-09-30	Reported	(m)	-$73.68M	(m)	(m)	(m)	$590.00K*	-$49.66M*	(m)	$56.97M	(m)	-$320.00K
2024-06-30	Reported	(m)	-$69.10M	(m)	(m)	(m)	$1.51M*	-$31.15M*	(m)	$49.70M	(m)	-$333.00K
2024-03-31	Reported	(m)	-$59.04M	(m)	(m)	(m)	$188.00K	-$46.19M	(m)	$44.25M	(m)	$412.00K
2023-09-30	Reported	(m)	-$55.68M	(m)	(m)	(m)	$1.20M*	-$48.08M*	(m)	$42.88M	(m)	-$157.00K
2023-06-30	Reported	(m)	-$55.62M	(m)	(m)	(m)	$2.13M*	-$33.22M*	(m)	$44.04M	(m)	-$220.00K
2023-03-31	Reported	(m)	-$49.05M	(m)	(m)	(m)	$2.21M	-$34.41M	(m)	$39.52M	(m)	$290.00K
2022-09-30	Reported	(m)	-$38.13M	(m)	(m)	(m)	$386.00K*	-$30.40M*	(m)	$29.43M	(m)	-$587.00K
2022-06-30	Reported	(m)	-$30.32M	(m)	(m)	(m)	$544.00K*	-$16.87M*	(m)	$22.15M	(m)	-$40.00K
2022-03-31	Reported	(m)	-$17.37M	(m)	(m)	(m)	$212.00K	-$18.43M	(m)	$19.36M	(m)	-$394.00K
2021-09-30	Reported	(m)	-$15.60M	(m)	(m)	(m)	$223.00K*	-$15.01M*	(m)	$18.89M	(m)	-$205.00K
2021-06-30	Reported	(m)	-$22.50M	(m)	(m)	(m)	$909.00K*	-$13.08M*	(m)	$18.38M	(m)	-$217.00K
2021-03-31	Reported	(m)	-$16.06M	(m)	(m)	(m)	$404.00K	-$20.71M	(m)	$16.31M	(m)	-$68.00K
2020-09-30	Reported	(m)	-$9.70M	(m)	(m)	(m)	$793.00K*	-$11.15M*	(m)	$13.04M	(m)	-$203.00K
2020-06-30	Reported	(m)	-$646.00K	(m)	(m)	(m)	$369.00K*	-$10.79M*	(m)	$10.72M	(m)	-$39.00K
2020-03-31	Reported	(m)	-$8.03M	(m)	(m)	(m)	$647.00K	-$13.07M	(m)	$11.79M	(m)	-$1.00K
2019-09-30	Reported	(m)	-$8.95M	(m)	(m)	(m)	$45.00K*	-$7.06M*	(m)	$9.75M	(m)	$5.00K
2019-06-30	Reported	(m)	-$10.51M	(m)	(m)	(m)	$265.00K*	-$8.75M*	(m)	$8.21M	(m)	-$29.00K
2019-03-31	Reported	(m)	-$11.76M	(m)	(m)	(m)	$335.00K	-$8.70M	(m)	$9.14M	(m)	$37.00K
2018-09-30	Reported	(m)	-$14.19M	(m)	(m)	(m)	$19.00K*	-$13.72M*	(m)	$6.25M	(m)	-$8.00K
2018-06-30	Reported	(m)	-$7.59M	(m)	(m)	(m)	$137.00K*	-$5.54M*	(m)	$5.42M	(m)	-$8.00K
2018-03-31	Reported	(m)	-$7.81M	(m)	(m)	(m)	$181.00K	-$8.22M	(m)	$5.57M	(m)	$12.00K
2017-12-31	Reported	(m)	-$8.05M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$8.64M	(m)	$264.00K	(m)	$14.00K*	-$8.63M*	(m)	$7.16M	(m)	(m)
2017-06-30	Reported	(m)	-$7.89M	(m)	(m)	(m)	$101.00K*	(m)	(m)	$6.11M	(m)	(m)
2017-03-31	Reported	(m)	-$7.99M	(m)	(m)	(m)	$137.00K	(m)	(m)	$5.90M	(m)	(m)
2016-12-31	Reported	(m)	-$5.46M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	(m)	-$7.33M	(m)	(m)	(m)	$46.00K*	(m)	(m)	$5.96M	(m)	(m)
2016-06-30	Reported	(m)	-$6.37M	(m)	(m)	(m)	$122.00K*	(m)	(m)	$5.10M	(m)	(m)
2016-03-31	Reported	(m)	-$5.66M	(m)	(m)	(m)	$83.00K	(m)	(m)	$4.36M	(m)	(m)
2015-12-31	Reported	(m)	-$2.60M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	(m)	-$820.00K	(m)	(m)	(m)	$218.00K*	(m)	(m)	$3.79M	(m)	(m)
2015-06-30	Reported	(m)	$199.00K	(m)	(m)	(m)	$106.00K*	(m)	(m)	$3.67M	(m)	(m)
2015-03-31	Reported	(m)	-$6.14M	(m)	(m)	(m)	$84.00K	(m)	(m)	$3.43M	(m)	(m)
2014-12-31	Reported	$240,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	(m)	$8.66M	(m)	(m)	(m)	$256.00K*	(m)	(m)	$3.22M	(m)	(m)
2014-06-30	Reported	(m)	$1.38M	(m)	(m)	(m)	$17.00K*	(m)	(m)	$2.57M	(m)	(m)
2014-03-31	Reported	(m)	$1.03M	(m)	(m)	(m)	$480.00K	(m)	(m)	$2.53M	(m)	(m)
2013-12-31	Reported	$2.19M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	(m)	$6.52M	(m)	(m)	(m)	(m)	(m)	(m)	$2.58M	(m)	(m)
2013-06-30	Reported	(m)	-$770.00K	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	Reported	(m)	$1.94M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$373.07M	(m)	(m)	(m)	$799.00K	-$279.12M	(m)	$300.94M	(m)	$1.02M
2024-12-31	Reported	(m)	-$279.30M	(m)	(m)	(m)	$3.08M	-$181.39M	(m)	$210.39M	(m)	-$4.09M
2023-12-31	Reported	(m)	-$214.05M	(m)	(m)	(m)	$5.62M	-$151.11M	(m)	$167.51M	(m)	-$292.00K
2022-12-31	Reported	(m)	-$129.14M	(m)	(m)	(m)	$2.89M	-$101.03M	(m)	$105.77M	(m)	$118.00K
2021-12-31	Reported	(m)	-$78.99M	(m)	(m)	(m)	$2.05M	-$69.50M	(m)	$75.46M	(m)	-$6.00K
2020-12-31	Reported	(m)	-$31.30M	(m)	(m)	(m)	$2.64M	-$48.12M	(m)	$50.52M	(m)	-$257.00K
2019-12-31	Reported	(m)	-$42.82M	(m)	(m)	(m)	$1.24M	-$4.71M	(m)	$38.84M	(m)	-$23.00K
2018-12-31	Reported	(m)	-$38.04M	(m)	(m)	(m)	$507.00K	-$34.72M	(m)	$23.63M	(m)	-$24.00K
2018-09-30	Rolling	(m)	-$37.64M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$32.09M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$32.39M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	(m)	-$32.58M	(m)	$311.00K	(m)	$315.00K	-$28.73M	(m)	$25.57M	(m)	(m)
2017-12-31	Rolling	(m)	-$32.58M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$29.99M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$28.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$27.15M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	(m)	-$24.82M	(m)	(m)	(m)	$279.00K	(m)	(m)	$19.83M	(m)	(m)
2016-12-31	Rolling	(m)	-$24.82M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$21.96M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$15.45M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$8.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	(m)	-$9.36M	(m)	(m)	(m)	$551.00K	(m)	(m)	$15.15M	(m)	(m)
2015-12-31	Rolling	(m)	-$9.36M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$6.72M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	$2.76M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	$3.94M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	$11.84M	(m)	(m)	(m)	(m)	$1.53M	(m)	(m)	$11.77M	(m)	$0.00
2014-12-31	Rolling	(m)	$11.11M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Rolling	(m)	$13.09M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	Rolling	(m)	$10.95M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	Rolling	(m)	$8.80M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	$10.42M	(m)	(m)	(m)	(m)	$156.00K	(m)	(m)	$12.30M	(m)	$0.00
2013-12-31	Rolling	(m)	$9.71M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	-$2.37M	(m)	(m)	(m)	(m)	$526.00K	(m)	(m)	$10.46M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Organon & Co. (OGN)	United States	$3.603B	17.03
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53
Arcus Biosciences, Inc. (RCUS)	United States	$3.188B	-8.52
Indivior Pharmaceuticals, Inc. (INDV)		$4.250B	14.09